Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. We are currently recruiting patients, and data-capturing all the questionnaires and feedback from the patients for the live study. Quite frankly, the clinical trials couldn’t have come at a better time.

Clinical Trials 113

Clinical Trials Chronic Pain Hydroponic Strains 113

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. Neurological Disorders: Several cannabinoids show promise in the treatment of neurological disorders, including multiple sclerosis (MS) and Parkinson’s disease.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Canna Care Docs

OCTOBER 3, 2023

On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. Some patients diagnosed with a terminal illness may begin to feel depressed or physically and mentally lethargic from the effects and symptoms of their disease.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

TheAnswerPage

MARCH 29, 2022

Has the National Institute of Drug Abuse (NIDA) recently provided funding for a clinical trial evaluating the efficacy of a CBD product as an opioid-sparing agent for patients with radiculopathic pain? The primary efficacy outcome is a change in opioid maintenance dose from baseline to the end of the treatment period.

Clinical Trials 52

Clinical Trials Safety Medicine Treatment 52

MMJ Recs

DECEMBER 28, 2023

In recent years, a significant shift has occurred in the perception of medical marijuana, transforming it from a controversial substance to a recognized and, in some places, a legal form of medical treatment. Medical cannabis, with its anxiolytic properties, offers a potential solution.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

TheAnswerPage

NOVEMBER 30, 2021

Psilocybin, the hallucinogen found in “magic mushrooms” has been used in clinical trials. According to the CSA, schedule I substances have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

Clinical Trials 52

Clinical Trials Safety Treatment THC 52

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Medicinal Marijuana Association

FEBRUARY 11, 2024

The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community. Potential for enhanced treatment outcomes with cannabis use. Improves optic nerve blood flow and protects retinal cells.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

JUNE 14, 2022

PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector. The good news is that innovations that completely change the lives of patients continue to emerge.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those enrolled in the study will receive 28 days of treatment and then be assessed by pain-rating scales.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JANUARY 31, 2022

The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with a severe or life-threatening illness.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Highlights from the presentation include: Declining PSA levels in treated patients. Declining circulating tumor cell (CTC) count in treated patients. Phase 2 trial underway. AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

OCTOBER 15, 2021

DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

The Blunt Truth

DECEMBER 23, 2020

assured, “The FDA’s first priority is to protect the health and safety of Americans. ” Importantly, the FDA, has not approved a marketing application for cannabis for the treatment of any disease or condition and thus has not determined that cannabis is safe and effective for any particular disease or condition.

CBD 103

CBD Food Safety Clinical Trials 103

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. This would answer questions about safety and efficacy, they said. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

CannaMD

SEPTEMBER 28, 2020

Patients around the world are reporting a sharp increase in sleep problems, and physicians have coined the term coronasomnia to describe the phenomenon. Many physicians turn to pharmacologic interventions to help patients sleep. However, there is a tradeoff between effectiveness and safety. Is there a more natural remedy?

Sleep 73

Sleep Clinical Trials Patients THC 73

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. See Deborah Brauser, FDA Permits Psilocybin to Be Tested for Refractory Depression, MEDSCAPE (Oct.

Law 105

Law Therapy Clinical Trials Research and Development 105

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JANUARY 19, 2022

He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives. We look forward to his guidance in helping us bring new, THC-based investigational medications into FDA approved clinical trials. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52